Beta Bionics, Inc. Common Stock BBNX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 57.2%+1.8pp | 55.4%+0.9pp | 54.5%+0.6pp | 53.9%0.0pp | 53.9%-1.2pp | |
| Operating margin | -70.1%+1.4pp | -71.5%+5.9pp | -77.4%+2.7pp | -80.1%-2.2pp | -78%-8.5pp | |
| Net margin | -60.3%+12.7pp | -73%+14.9pp | -87.9%+6.1pp | -94%+7.6pp | -101.6%-17.5pp | |
| EBITDA margin | -68.4%+1.5pp | -69.9%+6.1pp | -76%+2.6pp | -78.6%-2.3pp | -76.3%-8.6pp | |
| Free cash flow margin | -55.4%+0.6pp | -56.1%+12.3pp | -68.3%+11.2pp | -79.5%+5.6pp | -85.1%-5.8pp | |
| Returns | ||||||
| Return on equity | -22.7%— | —— | —— | —— | —— | |
| Return on assets | -20.7%+9.9pp | -30.6%— | —— | —— | —— | |
| Return on invested capital | -29.4%— | —— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.3×-0.1× | 0.4×— | —— | —— | —— | |
| Inventory turnover | 2.4×-0.2× | 2.6×-0.8× | 3.3×-0.1× | 3.4×-0.2× | 3.5×-0.5× | |
| Liquidity | ||||||
| Current ratio | 10.7×+2.0× | 8.7×-2.0× | 10.6×-4.0× | 14.7×-1.2× | 15.9×+9.6× | |
| Quick ratio | 9.7×+1.7× | 8×-1.9× | 9.8×-4.0× | 13.8×-1.1× | 14.9×+9.3× | |
| Cash ratio | 1.3×+0.3× | 1×-0.5× | 1.5×-0.3× | 1.8×-0.8× | 2.6×+1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $6.10-14.0% | $7.10+5.0% | $6.76-2.8% | $6.95-31.9% | $10.22+126% | |
| Valuation | ||||||
| Market capitalization | $708.98M-8.6% | $1.34B+55.3% | $863.75M+26.7% | $681.56M— | —— | |
| Enterprise value | $685.68M— | $1.32B+58.1% | $832.95M+27.5% | $653.17M— | —— | |
| Price / sales | 6.4×— | 13.4×+3.6× | 9.8×+1.0× | 8.7×— | —— | |
| Price / book | 2.6×— | 4.7×+1.7× | 2.9×+0.7× | 2.3×— | —— | |
| EV / sales | 6.2×— | 13.1×+3.7× | 9.4×+1.0× | 8.4×— | —— | |
| Free cash flow yield | -8.6%— | -4.2%+2.8pp | -7%+2.1pp | -9.1%— | —— | |
| Earnings yield | -9.4%— | -5.5%+3.6pp | -9%+1.8pp | -10.8%— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Beta Bionics, Inc. Common Stock's profit margins?
- Beta Bionics, Inc. Common Stock (BBNX) runs a 57.2% gross margin and a -70.1% operating margin, with a -60.3% net margin.
- Where do Beta Bionics, Inc. Common Stock's ratios come from?
- Every ratio is computed from Beta Bionics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
